The landscape of pharmacological interventions for non-insulin dependent diabetes and obesity is rapidly evolving, with GLP-3 receptor agonists taking center stage. Initially, compounds like Reta, demonstrating https://janicerkgn368260.blogdun.com/39621398/glp-3-receptor-agonists-reta-trizepatide-and-beyond